Skip to content

Study · Animal study (in vivo) · mouse · 2013

2 results

Attenuation of systemic morphine-induced analgesia by central administration of ghrelin and related peptides in mice.

Zeng P, Chen JX, Yang B, Zhi X, Guo FX, Sun ML, Wang JL, Wei J

Peptides7 Oct 2013Cited by 11 (Europe PMC)

PMID24113541 (opens in a new tab)DOI10.1016/j.peptides.2013.09.017 (opens in a new tab)PepBankPUB-24113541
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, intracerebroventricular GHRP‑2 decreased the analgesic effect of intraperitoneal morphine.

    In plain wordsIn mice, GHRP‑2 given into the brain weakened the pain relief from morphine.

    Peptide
    GHRP-2
    Outcome
    DecreaseMorphine-induced analgesia
    Study

    mousen: not reported in source

    Tail withdrawal test in mice
    Comparator
    Systemic morphine alone
    Outcome group
    Pain · Nervous system and cognition
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    Similarly, i.c.v. injection GHRP-6 and GHRP-2 which are the agonists of GHS-R1α, also decreased analgesia effect induced by morphine injected intraperitoneally in mice.
    1 context sentence
    Summary · context
    In the present study, intracerebroventricular (i.c.v.) injection of ghrelin (0.1, 1, 10 and 100 nmol/L) produced inhibition of systemic morphine (6 mg/kg, i.p.) analgesia in the tail withdrawal test.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice, pretreatment with the GHS-R1α antagonist [d-Lys(3)]-GHRP-6 did not block the anti-opioid activity of GHRP‑2 and related peptides.

    In plain wordsIn mice, a ghrelin receptor blocker did not stop GHRP‑2 from weakening morphine pain relief.

    Peptide
    GHRP-2
    Outcome
    No significant changeBlock of anti-opioid effect by GHS-R1a antagonist
    Study

    mousen: not reported in source

    Tail withdrawal test in mice
    Comparator
    Systemic morphine alone
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    Furthermore, these anti-opioid activities of ghrelin and related peptides were not blocked by pretreatment with the GHS-R1α selective antagonist [d-Lys(3)]-GHRP-6 (100 nmol/L, i.c.v.).
    1 context sentence
    Summary · context
    In the present study, intracerebroventricular (i.c.v.) injection of ghrelin (0.1, 1, 10 and 100 nmol/L) produced inhibition of systemic morphine (6 mg/kg, i.p.) analgesia in the tail withdrawal test.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.